Bladder preservation in muscle-invasive bladder cancer (MIBC) is evidence-based, patient-centered, and underutilized The latest IBCG consensus in European Urology offers global expert recommendations on when, how, and for whom bladder-sparing strategies are appropriate

Excited about #AACR25 and presenting our data

Some thoughts this evening regarding former President Biden‘s diagnosis and basics of #PCa screening. ⁦PBS News⁩ ⁦Penn State Health⁩ ⁦Amer. Urol. Assn.⁩ ⁦Penn State Urology⁩ pbs.org/newshour/show/…

🧬 Our study on molecular profiling of 99 cases of micropapillary urothelial carcinoma (MPUC): • Most common mutations: TP53, TERT, ARID1A, ERBB2 • ERBB2 alterations in 24%: Amplifications, Missense mutations (most common: p.S310F) • Only ERBB2 amplifications associated with:

Just in The Lancet Oncology The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements

Special thanks to clinical research teams at our site Cleveland Clinic MD & all sites 🌏 for their diligence in ensuring compliance with PROs & data entry. Amanda Nizam, MD Christopher Wee, MD Moshe Ornstein MD Tim Gilligan Case Comp Cancer Ctr

1/ On my final day as Chair of the Office of Education for Amer. Urol. Assn., a brief thread of reflections… 🧵

Excited to present our research on GLP-1 receptor agonists and their impact on weight loss across cancer types at the 2025 ASCO Annual Meeting! 🙌 A huge thank you to MSK’s incredible leaders—Drs. Urvi Shah, Sherry Shen, and Neil Iyengar—for their unwavering mentorship and

Great, unbiased, discussion with Jonathan Rosenberg MD Petros Grivas on ctDNA in #BladderCancer – promising, but not practice-changing yet. – ctDNA is prognostic, not yet predictive – Avoid overinterpreting current data – Use selectively in clinical “gray zones” – Enroll patients in

Bittersweet evening to celebrate the career and legacy of Guido Dalbagni a legend in the field of bladder cancer. We wish you luck in your next chapter! Memorial Sloan Kettering Cancer Center

🔎 Dr. Bishoy M. Faltas gives an overview of the #CLONEVO study, which is the first window-of-opportunity trial of a CDK4/6 inhibitor—abemaciclib—in muscle-invasive #bladdercancer: buff.ly/xNdrNug

Had so much fun discussing updates in #BladderCancer with community oncologist along with colleagues Oncology Brothers Drs. Rahul & Rohit Gosain and #GU colleagues Drs. Asha Tipirneni & Sindhuja Kadambi at the Upstate Cancer Symposium in Buffalo #endcancer

FGFR inhibition in FGFR3 altered UC doesn’t get the attention it deserves #GUARDSymposium2025 Its data platinum refractory UC is similar to EV. It’s used in late disease. Sadly there are no R3s 1st line or combo studies. The survey below shows enthusiasm post EVP OncoAlert

LIVE DAY 2 #GUARDSymposium2025 Our OncoAlert 🚨Faculty Tom Powles 🇬🇧Discusses: How to treat Advanced #BladderCancer patients after progression to Enfortumab-Pembrolizumab? Tom Powles Syed A Hussain Matt Galsky Andrea Necchi Félix Guerrero-Ramos Mario AlvarezMaestro Urbano Anido

Congratulations to Dr. Porten on her appointment as Chief of Urologic Oncology! A role that recognizes her exceptional clinical expertise, research leadership, and long-standing commitment to advancing care for patients with genitourinary cancer. urology.ucsf.edu/news/all/20250…

Honored to be nominated to the Executive Committee of the Society for Basic Urologic Research Society for Basic Urologic Research | SBUR! If elected, I’ll work to expand the society’s scientific scope, enhance mentorship pathways, and foster collaborations that empower the next generation of investigators.

Vote for Bishoy!

Congratulations to Ali Aminsharifi, MD, Sri Saran Manivasagam, & Jay Raman on your most recent article publication on PubMed! Article Link: pubmed.ncbi.nlm.nih.gov/40551661/

I'm excited to start at UChicagoCancerCenter as chair of the Ben May Dept for Cancer Research and the Ludwig Cancer of UChicago! Things are moving already & we launched a faculty search for tumor microenvironment--take a look & apply! apply.interfolio.com/169039

Treatment approaches for node-positive locally advanced #BladderCancer. Surgery or systemic therapy? Shilpa Gupta Cleveland Clinic & Félix Guerrero-Ramos Department of Urology, Hospital 12 De Octubre join Ashish M. Kamat, MD, MBBS MD Anderson Cancer Center to debate: 🧬 EV+pembro as new SOC? 🧠 Multidisciplinary strategy? 🔪 Is radical